The products of oncogenes frequently localize to the cell membrane and may possess extracellular domains. Transformation of cells by high molecular weight DNA from human tumors can be mediated by oncogenes and may also result in the expression of new tumor-associated antigens. The use of NIH 3T3 cells transfected with high molecular weight DNA from human tumors as an immunogen has resulted in the production of human tumor--selective monoclonal antibodies. The purpose of this proposal is to investigate the immunotherapeutic potential of monoclonal antibody 45-2D9 produced by immunizing with the NIH 3T3 tertiary c-Ha-ras transformant 45-342. The NIH 3T3 tertiary transfectant 45-342 expresses a 74,000 Mr glycoprotein recognized by the 45-2D9 antibody. The 45-2D9 has been conjugated to the A chain of ricin. The stability, structural integrity, and biologic activity of the 45-2D9 immunotoxin will be deterimined in vivo and compared to the native antibody. Structural half-life and clearance studies of 125I labeled 4502D9 and immunotoxin will be performed will monitoring by SDS- polyacrylamide gel electrophorsis. Biodistribution studies of radiolabeled 4502D9 antibody and immunotoxin will be performed in mice bearing 45-342 cells will spontaneously metastasize in nu/nu mice and form lung colonies in irradiated Balb/c mice following intravenous injection. Thus an ideal model of established disseminated solid tumor is available to study the therapeutic potential of the 45-2D9 antibody and immunotoxin. Potentiators of immunotoxin activity and biochemical modifications of the immounotoxin will be evaluated in vivo. Modification of the immunotoxin by use of antibody fragments, more stable toxin-antibody linkages, and antibody-potentiator conjugates will be studied. Possible synergistic therapeutic effects between the antibody, immunotoxin, and other biologic response modifiers (IL-2, LAK cells, interferon) will be investigated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA045187-02
Application #
3482589
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1987-07-01
Project End
1992-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Roth, J A; Cristiano, R J (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89:21-39
Srinivasan, R; Maxwell, S A (1996) A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region. Oncogene 12:193-200
Mukhopadhyay, T; Roth, J A; Maxwell, S A (1995) Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11:999-1003
Owen-Schaub, L B; Zhang, W; Cusack, J C et al. (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-40
Mukhopadhyay, T; Roth, J A (1995) Antisense therapy for cancer. Cancer J Sci Am 1:233-42
Roussel, E; Gingras, M C; Grimm, E A et al. (1995) High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. Cancer Immunol Immunother 41:1-9
Fujiwara, T; Mukhopadhyay, T; Cai, D W et al. (1994) Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line. Int J Cancer 56:834-9
Maxwell, S A (1994) Two-dimensional gel analysis of p53-mediated changes in protein expression. Anticancer Res 14:2549-56
Maxwell, S A (1994) Selective compartmentalization of different mdm2 proteins within the nucleus. Anticancer Res 14:2541-7
Mukhopadhyay, T; Tainsky, M; Cavender, A C et al. (1991) Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 51:1744-8

Showing the most recent 10 out of 14 publications